Cost-Effectiveness of Tenofovir Instead of Zidovudine for Use in First-Line Antiretroviral Therapy in Settings Without Virological Monitoring

PLoS ONE - United States
doi 10.1371/journal.pone.0042834
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Public Library of Science (PLoS)

Related search

Cost-Effectiveness of Antiretroviral Therapy for Prevention

Current HIV Research
VirologyInfectious Diseases
2011English

Lopinavir/Ritonavir Monotherapy After Virologic Failure of First-Line Antiretroviral Therapy in Resource-Limited Settings

AIDS
Infectious DiseasesAllergyImmunology
2012English

Effectiveness of First-Line Antiretroviral Therapy in the IPEC Cohort, Rio De Janeiro, Brazil

AIDS Research and Therapy
VirologyMolecular MedicinePharmacology
2014English

Effect of Tuberculosis Co Infection on Virological Failure in HIV Patients on First Line of Highly Active Antiretroviral Therapy

International Journal of Current Microbiology and Applied Sciences
2017English

Use of Third Line Antiretroviral Therapy in Latin America

PLoS ONE
Multidisciplinary
2014English

Cost-Effectiveness of Highly Active Antiretroviral Therapy in South Africa

PLoS Medicine
BiochemistryBiotechnologyMolecular BiologyCell BiologyMedicine
2005English

First-Line Antiretroviral Therapy With Efavirenz Plus Tenofovir Disiproxil Fumarate/Emtricitabine or Rilpivirine Plus Tenofovir Disiproxil Fumarate/Emtricitabine: A Durability Comparison

HIV Medicine
Health PolicyInfectious DiseasesPharmacology
2018English

Antiretroviral Therapy Adherence Monitoring and Its Impact on Immuno-Virological Outcome

BMC Infectious Diseases
Infectious Diseases
2014English

Cost-Effectiveness of First-Line Therapy for Advanced Non-Small Cell Lung Cancer (Nsclc)

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2014English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy